Mr. Eric C. Hsu - 19 Dec 2025 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Reporting relationship: Sr. VP, Pre-Clinical Res/Dev
Issuer ticker: INM
Reported as of: 19 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Dec 2025, 11:39:39 UTC
Prior SEC filing: 17 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Eric A. Adams, attorney-in-fact for Mr. Eric C. Hsu

Filing notes and source

Key filing fact

Mr. Eric C. Hsu filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 19 Dec 2025.

Key facts

This page summarizes Mr. Eric C. Hsu's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Dec 2025, 11:39.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001817867 Primary reporting owner

Relationship: Sr. VP, Pre-Clinical Res/Dev
Address: C/O INMED PHARMACEUTICALS INC., 1445-885 WEST GEORGIA ST., VANCOUVER, BRITISH COLUMBIA, CANADA
Signature: /s/ Eric A. Adams, attorney-in-fact for Mr. Eric C. Hsu
Signature date: 19 Dec 2025

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INM transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The options were granted on 12/19/2025 and will vest in equal installments monthly, in arrears, over 36 months (1/36 per month)